EZH2 and neoplasm: Both Src and MEK signaling kinases are co-activated in 31% of HGSOC. Combined treatment with Src inhibitor saracatinib and MEK inhibitor selumetinib decreased ALDH1+ cell sphere formation and loss of ALDH1+ OCSCsLncRNA HOTAIR is upregulated in HGSOC and especially in ALDH1+ OCSCs. Peptide nucleic acid PNA3 inhibits HOTAIR, and enhancer of zeste homolog 2 (EZH2) interaction and when combined with DNMT inhibitor guadecitabine abrogates ALDH1+ spheroid formation and decreases their number and tumor-promoting ability